NCT06487858 2026-03-18
A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors
BeOne Medicines
Phase 1 Active not recruiting
BeOne Medicines
Sichuan University
BeiGene
InxMed (Shanghai) Co., Ltd.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.